We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Novel Imaging Technique Could Improve Cancer Screening in Areas with Limited Access to PET Scans

By MedImaging International staff writers
Posted on 14 Apr 2022
Print article
Image: Cerenkov imaging of a thyroid tumor captures its location and high activity (Photo courtesy of MSK)
Image: Cerenkov imaging of a thyroid tumor captures its location and high activity (Photo courtesy of MSK)

Positron emission tomography (PET) is one of the most widely used diagnostic tools in cancer care. PET scans show the location of a tumor, usually based on increased glucose intake, a hallmark of cancer cells. Despite their effectiveness, PET scans can be hard to access in developing countries and rural areas. PET scanners are expensive and many regions lack the infrastructure required to house them and support their operation. There has been a pressing need for cheaper ways to do imaging to improve cancer care for a much larger population around the world. Now, a team of researchers has begun testing a new technology that could provide a cheaper, faster imaging approach for areas where access to PET scans is limited.

The technique being tested by researchers at Memorial Sloan Kettering Cancer Center (MSK, New York, NY, USA) involves employing specialized cameras to detect Cerenkov light, a faint glow that is naturally emitted by radioactive tracers. PET scans require these radioactive tracers to detect the increased glucose metabolism of cancer cells. The new approach could make it possible to get critical information with most clinically used radioactive tracers but without the PET machine - and at a fraction of the cost. The researchers demonstrated the effectiveness of Cerenkov light in this setting in a clinical trial of nearly 100 patients.

For five different radiotracers, Cerenkov proved to be as accurate for showing tumor location as conventional imaging methods like PET and computed tomography (CT). For some patients who were receiving radiation therapy, Cerenkov also provided information on whether their tumors were shrinking or responding in other ways to the treatment. The clinical trial was the largest study to date testing Cerenkov imaging. While it validates the technique’s potential as a cheaper and more portable imaging approach than PET, the researchers are already looking for further refinements to make it even more useful. This includes imaging the entire body (rather than specific sites), imaging during an operation to help guide surgical decisions, and using a more sensitive camera to make image acquisition even faster and easier.

“This imaging technique based on Cerenkov light could be used instead of expensive PET scans in many cases,” said Jan Grimm, a radiologist and molecular imaging specialist at MSK, who led the team. “It wouldn’t replace PET because it cannot provide the same level of detail, precise measurement, or depth penetration. But having a cheaper and faster imaging approach to select patients that should undergo a PET scan or as a first-line test could provide a huge benefit to many developing areas.”

Related Links:
Memorial Sloan Kettering Cancer Center 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Computed Tomography (CT) Scanner
Aquilion Serve SP
New
Pre-Op Planning Solution
Sectra 3D Trauma
New
Ultrasound System
Acclarix AX9

Print article
Radcal

Channels

MRI

view channel
Image: Shorter scan to diagnose prostate cancer can increase availability and reduce cost (Photo courtesy of 123RF)

Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality

Prostate cancer ranks as the most prevalent cancer among men. Over the last decade, the introduction of MRI scans has significantly transformed the diagnosis process, marking the most substantial advancement... Read more

Nuclear Medicine

view channel
Image: The radiotheranostic platform employs a MUC16-targeting humanized antibody, huAR9.6 (Photo courtesy of MSK)

New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively

Ovarian cancer is the most lethal gynecological cancer, with less than a 30% five-year survival rate for those diagnosed in late stages. Despite surgery and platinum-based chemotherapy being the standard... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.